Evidence map›Paper›PMID 25925382›Full record

ArticleCritical care (London, England)2015

Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants.

David Faraoni, Jerrold H Levy, Pierre Albaladejo, Charles-Marc Samama, Groupe d’Intérêt en Hémostase Périopératoire

Abstract read
In one paragraph

Article in Critical care (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Perioperative management of anticoagulant therapy.Innovative surgical sciences · 2019
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. [Perioperative handling of anticoagulation].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2018
    Review
  17. Article
  18. Article
  19. The role of new oral anticoagulants in orthopaedics: an update of recent evidence.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2017
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

David FaraoniDepartment of Anesthesiology, Peri-operative and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA. david.faraoni@childrens.harvard.edu.
Jerrold H LevyDepartment of Anesthesiology and Intensive Care, Duke University School of Medicine, Durham, NC, 27710, USA. jerrold.levy@duke.edu.
Pierre AlbaladejoDepartment of Anesthesiology and Intensive Care Medicine, Grenoble University Hospital, Grenoble, 38043, France. PAlbaladejo@chu-grenoble.fr.
Charles-Marc SamamaDepartment of Anesthesiology and Intensive Care Medicine, Assistance Publique- Hôpitaux de Paris, Cochin University Hospital, Paris, 75181, France. marc.samama@cch.aphp.fr.
Groupe d’Intérêt en Hémostase Périopératoire

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Perioperative management of patients treated with the non-vitamin K antagonist oral anticoagulants is an ongoing challenge. Due to the lack of good clinical studies involving adequate monitoring and reversal therapies, management requires knowledge and understanding of pharmacokinetics, renal function, drug interactions, and evaluation of the surgical bleeding risk. Consideration of the benefit of reversal of anticoagulation is important and, for some low risk bleeding procedures, it may be in the patient's interest to continue anticoagulation. In case of major intra-operative bleeding in patients likely to have therapeutic or supra-therapeutic levels of anticoagulation, specific reversal agents/antidotes would be of value but are currently lacking. As a consequence, a multimodal approach should be taken which includes the administration of 25 to 50 U/kg 4-factor prothrombin complex concentrates or 30 to 50 U/kg activated prothrombin complex concentrate (FEIBA®) in some life-threatening situations. Finally, further studies are needed to clarify the ideal therapeutic intervention.

Indexed as

Oral MedicineAnticoagulantsAntithrombinsFactor Xa InhibitorsHemorrhageHumansMedication Therapy ManagementPerioperative CarePyrazolesPyridonesRivaroxabanVitamin KAnticoagulantsAntithrombinsapixabanFactor Xa InhibitorsPyrazolesPyridonesRivaroxabanVitamin K

Identifiers

PMID25925382
PMCPMC4414429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.